Streetbeat News

CCAP

Crescent Capital BDC, Inc.

https://www.crescentbdc.com

Industry

Asset Management

Crescent Capital BDC, Inc. is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.

Open

19.03

Mkt cap

706M

Volume

60K

High

19.15

P/E Ratio

7.45

52-wk high

19.63

Low

19.01

Div yield

0.11

52-wk low

15.91

Crescent Capital's Q3 earnings report highlights strong dividend coverage and NAV growth, indicating a resilient portfolio. With a 9.7% dividend yield supported by earnings, and a portfolio valued at $1.6B concentrated in health care and software, CCAP shows financial health and high-quality underwriting.

Portfolio Pulse from

November 13, 2024 | 12:45 pm

Crescent Capital BDC (CCAP) reported Q3 earnings of $0.64 per share, surpassing the Zacks Consensus Estimate of $0.57 per share, and showing growth from $0.59 per share a year ago.

Portfolio Pulse from

November 12, 2024 | 1:45 pm

Crescent Capital BDC (NASDAQ:CCAP) has received mixed analyst ratings over the past three months, with a consistent average price target of $19. Analysts have varied in their ratings from 'Buy' to 'Equal-Weight', reflecting differing views on the company's performance. Despite a decline in revenue, Crescent Capital BDC shows strong profitability and financial health with high net margins and ROE.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 3:00 pm

Ladenburg Thalmann has initiated coverage on Crescent Capital BDC with a Buy rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 1:41 pm

Crescent Capital BDC (NASDAQ:CCAP) has received mixed analyst ratings over the past three months, with recent assessments showing a slight decline in average price targets. Analysts have adjusted their ratings and price targets, reflecting varied perspectives on the company's future performance. Key financial metrics indicate challenges in revenue growth but strong profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 6:00 pm

B of A Securities analyst Derek Hewett maintains a Buy rating on Crescent Capital BDC (NASDAQ:CCAP) but lowers the price target from $20 to $19.

Portfolio Pulse from vivek@benzinga.com

August 15, 2024 | 5:11 pm

Wells Fargo analyst Finian O'Shea maintains an Equal-Weight rating on Crescent Capital BDC (NASDAQ:CCAP) but lowers the price target from $19 to $18.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:40 pm

Crescent Capital BDC (NASDAQ:CCAP) reported Q2 earnings of $0.59 per share, beating the analyst estimate of $0.58. Sales were $48.95 million, surpassing the $47.65 million estimate. Both earnings and sales showed year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:17 pm

Crescent Capital BDC (NASDAQ:CCAP) has received mixed analyst ratings over the past quarter, with two analysts being somewhat bullish and two indifferent. The average 12-month price target has increased to $18.75 from $17.75. Analysts from Wells Fargo, Keefe, Bruyette & Woods, and Raymond James have raised their price targets, reflecting positive sentiment. Despite high debt levels, Crescent Capital BDC shows strong revenue growth, net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

July 26, 2024 | 1:01 pm

Wells Fargo analyst Finian O'Shea maintains an Equal-Weight rating on Crescent Capital BDC (NASDAQ:CCAP) and raises the price target from $18 to $19.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.